Park Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSK

Key Points

• Park Place Capital Corp increased its investment in GSK PLC Sponsored ADR by 388.5% during the second quarter, owning a total of 10,240 shares worth approximately $399,000.
• GSK recently reported earnings per share (EPS) of $1.23 for the last quarter, surpassing estimates, and its revenue reached $10.64 billion, significantly above expectations.
• The company announced a quarterly dividend of $0.4206, translating to an annualized yield of 3.9%, with a payout ratio of 77.78%.

Park Place Capital Corp lifted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 388.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,240 shares of the pharmaceutical company's stock after acquiring an additional 8,144 shares during the quarter. Park Place Capital Corp's holdings in GSK were worth $399,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. HHM Wealth Advisors LLC lifted its position in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 460 shares during the period. Costello Asset Management INC purchased a new stake in shares of GSK in the 1st quarter worth approximately $31,000. Richardson Financial Services Inc. lifted its position in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after purchasing an additional 472 shares during the period. Olde Wealth Management LLC purchased a new stake in shares of GSK in the 1st quarter worth approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its position in shares of GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Performance

Shares of NYSE GSK opened at $43.16 on Wednesday. The company's fifty day moving average price is $39.40 and its 200 day moving average price is $38.60. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $43.32. The company has a market capitalization of $87.81 billion, a PE ratio of 19.98, a price-to-earnings-growth ratio of 2.05 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same period last year, the firm posted $0.43 earnings per share. The company's revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date of this dividend is Friday, August 15th. GSK's payout ratio is presently 77.78%.

Wall Street Analyst Weigh In

GSK has been the subject of several research reports. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.